Enlivex Therapeutics Files 2024 Annual Report
Ticker: ENLV · Form: 20-F · Filed: Apr 30, 2025 · CIK: 1596812
| Field | Detail |
|---|---|
| Company | Enlivex Therapeutics Ltd. (ENLV) |
| Form Type | 20-F |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, pharmaceutical, sec-filing
TL;DR
Enlivex Therapeutics filed its 2024 20-F, check it for the latest on their pharma biz.
AI Summary
Enlivex Therapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, formerly known as Bioblast Pharma Ltd., is based in Tel Aviv and operates in the pharmaceutical preparations sector. The filing covers its operations and financial status as of April 30, 2025.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Enlivex Therapeutics' performance and financial health for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Enlivex Therapeutics is subject to inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year End (The report covers the full fiscal year ending December 31, 2024.)
- 20250430 — Filing Date (The annual report was filed with the SEC on April 30, 2025.)
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Bioblast Pharma Ltd. (company) — Former company name
- 001-36578 (dollar_amount) — SEC file number
- 20241231 (dollar_amount) — Fiscal year end date
- 20250430 (dollar_amount) — Filing date
FAQ
What was Enlivex Therapeutics Ltd.'s former company name?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd., with a name change occurring on September 19, 2016.
What is the SEC file number for Enlivex Therapeutics Ltd.?
The SEC file number for Enlivex Therapeutics Ltd. is 001-36578.
On what date was this 20-F annual report filed?
This 20-F annual report was filed on April 30, 2025.
What is the fiscal year end for Enlivex Therapeutics Ltd.?
The fiscal year end for Enlivex Therapeutics Ltd. is December 31.
Where is Enlivex Therapeutics Ltd. headquartered?
Enlivex Therapeutics Ltd. is headquartered in Tel Aviv, Israel, with its business address at 37 Derech Menachem Begin St., 15th Floor, Tel Aviv, 6522042.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 30, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).